On-Demand Webcast


Program Content

  • Tx Options for MDS
    A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 13, 2022

    Expires: January 12, 2023

    View Activity


cover img faculity

Michael R. Savona, MD, FACP

Director of Leukemia Research
Senior Investigator, Hematologic Malignancies Research and Drug Development
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancers
Tennessee Oncology
Nashville, Tennessee

cover img faculity

Jacqueline S. Garcia, MD

Assistant Professor, Medicine
Harvard Medical School
Adult Leukemia Program
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Provided by

ProCE Banner


AbbVie Inc.

Gamida Cell Ltd


Gilead Sciences, Inc.

Karyopharm Therapeutics Inc.

Takeda Pharma USA Inc Takeda Onc Co